The US HBOT market in 2026 looks very different from a decade ago. The hospital tier is mature — anchored by 180 UHMS-accredited centers tied to wound care. The wellness tier is growing fast and crowded.
This report covers the size, structure, and direction of the market. We use our own database of 1,570 centers, the UHMS list, FDA 510(k) records, and CMS coverage data.
We cover clinic counts by tier, insurance trends, chamber-maker share, and where the puck is going. The market is at an inflection point.
How big is the US HBOT market
A reasonable count of US HBOT centers in 2026 is about 1,570. That figure comes from our own directory build that cross-references state licensure data, hospital wound-care listings, and the UHMS public directory.
About 60% of those centers are hospital-based wound-care programs. The remainder are chiropractor-affiliated, wellness-brand, or independent operators using soft-shell or hybrid chambers.
Revenue estimates vary widely. Industry analysts at Grand View Research 2024 pegged the US HBOT services market at roughly $1.6 billion. The wellness tier accounts for a growing share but is still smaller than the hospital tier in dollar terms.
The UHMS-accredited tier
The 180 UHMS-accredited facilities form the trust backbone. They cover all 13 FDA-cleared indications and bill Medicare under CMS LCD L33718.
Of those 180, 57 hold the higher "with distinction" status. Distinction signals an extra layer of safety review and outcome tracking. The proportion — 32% with distinction — has held steady for several years.
The accredited tier is concentrated in coastal and high-population states. New York leads at 29 facilities, with California at 23, Florida at 18, Texas at 17, and Illinois at 11. Six states have zero UHMS-accredited facilities — patients there travel out of state for covered care.
For a deeper look at what UHMS accreditation actually means, see our accreditation explainer.
The wellness tier
The wellness tier is younger and harder to count. Our database flags about 627 centers that operate primarily outside the hospital wound-care model. Most use soft-shell or hybrid chambers at 1.3 to 1.5 ATA.
Three patterns dominate this tier. The first is chiropractic-affiliated clinics with one chamber added to an existing practice. The second is dedicated mild-HBOT studios that often pair with cryotherapy, red-light, and IV-drip services.
The third pattern is the multi-location brand chain.
The chain segment is led by Restore Hyper Wellness, which operates about 200 corporate and franchise locations. The chain charges $80 to $150 per session and bundles HBOT with cold plunge, IV drips, and other recovery services.
Other multi-location operators include Hyperbaric Centers of NY and Texas, and a handful of regional brands. Aviv Clinics — the brand behind the 60-session anti-aging protocol — runs a single US location in Boca Raton. See our evidence vs marketing analysis for details on that protocol.
The chamber-maker market
The supply side is led by a small number of FDA-cleared makers. The openFDA 510(k) database 2025 lists 69 unique chambers cleared under product code CBF.
Hard-shell hospital chambers come mainly from Sechrist, Perry Baromedical, ETC, Pan-America, and Reimers. Sechrist holds the largest hospital share, with many thousands of installed units.
Soft-shell wellness chambers come mainly from OxyHealth, Summit to Sea, and Newtowne Hyperbarics. The OxyHealth Vitaeris 320 is the most widely deployed soft-shell unit in US wellness clinics.
For the full FDA-cleared chamber list, see our FDA chambers complete list.
Insurance coverage trends
Insurance coverage drives the hospital tier. The 13 FDA-cleared indications cover Medicare via CMS LCD L33718, with most commercial insurers tracking that list. Average reimbursement per session is about $700 to $800 (CMS HBOT fee schedule 2024).
Insurance does not cover the off-label uses that drive wellness demand — brain injury, autism, anti-aging, recovery, and long COVID. That gap is the wellness tier's market.
Two coverage shifts to watch. First, the VA's slow expansion of HBOT access for traumatic brain injury after the 2024 BRAIN Initiative grant updates. Second, a small but rising number of commercial insurers covering sudden sensorineural hearing loss.
For full context on what major institutions cover (and what they don't), see our institutional silence analysis.
Off-label demand drivers
The wellness tier is driven by demand for off-label use that mainstream medicine does not endorse. The biggest demand drivers in 2026:
Long COVID. A JAMA Network Open 2024 review of post-COVID research highlighted the Shamir RCT as the most promising signal. We covered the Shamir RCT in detail in our long COVID analysis.
Anti-aging. Driven by the 2020 Hadanny telomere paper and aggressive marketing from boutique clinics. Demand is concentrated in high-income coastal markets.
Athletic recovery. NFL and NBA players have driven visibility. We covered the gap between celebrity endorsements and outcomes data in our athletic recovery analysis.
Brain injury, ADHD, and autism. The off-label market for neurological indications is the most ethically fraught segment. Data quality varies widely. See the HBOT-for-ADHD evidence in detail for the trial-by-trial ADHD evidence breakdown.
Regulatory landscape
Three regulatory threads matter in 2026. First, FDA's 2014 consumer safety alert on off-label HBOT marketing is still on the books and still relevant. The agency has not updated its list of 13 cleared indications in 15 years.
Second, state-level oversight is uneven. Some states require facility licensure for HBOT; others rely entirely on FDA chamber clearance plus practitioner licensure. There is no national HBOT-clinic license.
Third, the wellness tier operates in a regulatory gray zone. Soft-shell chambers at 1.3 ATA are FDA-cleared for one specific use (altitude sickness). Their use for any other indication is technically off-label, but enforcement is rare.
Pricing trends
Hospital pricing tracks Medicare reimbursement, which has been roughly flat ($700 to $800 per session) for several years. A 40-session course bills Medicare $25,000 to $30,000.
Wellness pricing has bifurcated. Chiropractic-affiliated clinics have stayed at $80 to $100 per session. Premium wellness brands have pushed to $150 to $250.
The 60-session anti-aging protocol from Boca Raton operates at the top of the market at roughly $50,000 per course. That pricing is consistent with the Israeli source research but well outside the typical US HBOT price band (Hadanny et al., Aging 2020).
Patient demographics
Hospital HBOT patients skew older and more medically complex. The median patient is in their late 60s with diabetic foot ulcer, radiation tissue injury, or chronic osteomyelitis as the primary indication.
Wellness HBOT patients are younger and self-pay. The largest cohort is 35 to 55, with disposable income and a specific off-label condition or wellness goal driving the visit. Athletic recovery and anti-aging skew male and female respectively.
The pediatric segment is small but ethically fraught. Most pediatric HBOT in hospital settings treats radiation injury after childhood cancer. Off-label pediatric HBOT (mainly for autism and cerebral palsy) is offered by some wellness clinics. See the cerebral palsy evidence atlas for the full investigational evidence breakdown.
Where the puck is going
Three trends to watch through 2027. Insurance coverage for sudden sensorineural hearing loss is expanding slowly across commercial plans. If Medicare follows, that indication could materially grow the hospital tier.
Long COVID research could shift the off-label market. If the Shamir RCT results replicate in larger trials, US hospital systems may add long COVID HBOT to covered services.
Wellness consolidation. Restore Hyper Wellness and a handful of competitors are scaling fast. Within 24 months we expect 2 to 3 national chains to dominate the wellness tier.
What the market still lacks
Three structural gaps remain. First, no national HBOT clinic license — quality varies wildly between operators. Second, no public outcome registry exists to compare success rates between centers.
Third, no patient cost-comparison tool — pricing transparency is poor.
These gaps create both risk (patients pay for ineffective care) and opportunity (an evidence-tracker market segment is growing). Our database project is one attempt to fill some of those gaps.
Bottom line
The US HBOT market in 2026 splits cleanly into two tiers with different economics, evidence bases, and patient profiles. The hospital tier is mature, regulated, and insurance-funded. The wellness tier is growing fast and largely unregulated.
For patients, the tier-choice decision should follow the indication. FDA-cleared use means hospital tier. Off-label use means wellness tier with eyes open and budget set.
For operators and investors, the wellness tier is the growth story but carries regulatory and reputation risk. The hospital tier is steadier but capital-intensive.
Related Reading
- FDA-cleared HBOT chambers: complete list
- UHMS-accredited HBOT facilities: what certification means
- What major institutions are not saying about HBOT
- Aviv Clinics: evidence vs marketing
- HBOT for athletic recovery: endorsements vs evidence
Frequently asked questions
How many HBOT clinics are in the US?
About 1,570 by our count, split roughly 60% hospital and 40% wellness. Of those, 180 hold UHMS accreditation and 57 hold the higher distinction status.
How big is the US HBOT services market?
Industry analysts put the US HBOT services market at roughly $1.6 billion in 2024. The hospital tier accounts for most revenue today, with the wellness tier growing faster.
Which chamber maker has the largest US share?
Sechrist Industries leads the hospital monoplace market. OxyHealth leads the wellness soft-shell market. Perry Baromedical, ETC, and Pan-America compete for hospital multiplace installations.
Is HBOT covered by Medicare?
Yes, for 13 specific indications listed in CMS LCD L33718. Off-label uses such as brain injury, autism, anti-aging, and recovery are not covered by Medicare or most commercial insurers.
Is the HBOT market growing?
Yes, on both tiers. Hospital growth tracks diabetes and chronic-wound prevalence. Wellness growth tracks consumer interest in recovery, anti-aging, and off-label use of HBOT for neurological conditions.
Medical disclaimer: This report is informational and does not constitute medical advice. Market figures are estimates based on public data sources and may not reflect current values. HBOT carries real risks including ear injury, oxygen-related harm, and chamber fire. The FDA has cleared HBOT for 13 specific uses; uses outside that list are off-label.
-- The HBOT Finder Team